A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification
Authors' conclusion
Patients with D2TRA-other are indistinguishable from non-D2TRA patients at baseline, indicating the former cohort does not appear to have any predictive value during the early stages of b/tsDMARD treatment, unlike what occurs in patients with D2TRA-inefficacy.
Study context
- Population
- Patients with RA treated with b/tsDMARDs in clinical practice; characteristics assessed before the first b/tsDMARD122 difficult-to-treat rheumatoid arthritis (D2TRA)
- Participants
- 253 patients
- Exposure
- D2TRA due to inefficacy vs D2TRA from other causes vs non-D2TRA
- D2TRA-inefficacyn = 86
- D2TRA-othern = 36
- Non-D2TRAn = 131reference
- Outcome
- Baseline characteristics before first b/tsDMARD
Methodological detailsclinical practice cohort, bivariate logistic regression
- Clinical practice cohort
- Bivariate logistic regression
Main finding
As reported in the abstract
- D2TRA-other vs D2TRA-inefficacy: no differences in gender, age at start of b/tsDMARD, age at RA diagnosis, socioeconomic status, anxiety-depression or other comorbidities
- D2TRA-other had less extra-articular manifestations and lower DAS28 at start of first b/tsDMARD than D2TRA-inefficacy
- Non-D2TRA vs D2TRA-other: no differences in sociodemographic characteristics or disease activity
Observational data: associations, not effects.
Original publication
A paradigm of difficult-to-treat rheumatoid arthritis: subtypes and early identification. Clin Exp Rheumatol. Published 19 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →